Internal Medicine
RCT: In patients with cirrhosis treated with TIPS, prophylactic rifaximin reduced the risk for Hepatic Encephalopathy
7 Feb, 2021 | 21:10h | UTCThe Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt: A Randomized Controlled Trial – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentary: Rifaximin prevents overt hepatic encephalopathy after TIPS – HealthDay
Commentary on Twitter
New findings published in @AnnalsofIM:
In patients with #cirrhosis treated with TIPS, rifaximin was well tolerated and reduced the risk for overt HE. #Rifaximin should therefore be considered for prophylaxis of post-TIPS HE https://t.co/d2p9dfcx3s. pic.twitter.com/M7zwmUxQA3
— Annals of Int Med (@AnnalsofIM) February 2, 2021
RCT: Posaconazole noninferior to voriconazole for primary treatment of invasive aspergillosis
7 Feb, 2021 | 21:00h | UTCPosaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
SR/MA: Up to a third of patients may discontinue thyroid hormone replacement and remain euthyroid
7 Feb, 2021 | 21:02h | UTCClinical Outcomes After Discontinuation of Thyroid Hormone Replacement: A Systematic Review and Meta-Analysis – Thyroid (link to abstract – $ for full-text)
Commentary: A Third Discontinuing Levothyroxine Have Normal Thyroid Levels – Medscape (free registration required)
Commentaries on Twitter
Hard to believe that simply treating hypothyroidism may fit into “Things We Do For No Reason.”
But >1/3 of people on thyroid replacement stay euthyroid after stopping meds.
See article for results, predictors of euthyroidism, & de-escalation strategies.https://t.co/i1f04FnbPk pic.twitter.com/fGLAbjNo5B
— David A. Cohen (@DavidACohen_MD) January 21, 2021
(thread – click for more)
#endocation #endotwitter #endotips #endorules
Hypothyroidism?: Third of Patients Treated for
Hypothyroidism May Not Require Thyroid Hormones❗️https://t.co/iAZcwFB5Ul✅Hypothyroidism: 5% of population, age dependent
✅NHANES: 6.4% reported use of levothyroxine (LT4)1/
— Fady Hannah-Shmouni, MD FRCPC (@DrShmouni) January 14, 2021
Guideline synopsis: Management of immunotherapy-related toxicities in patients treated with immune checkpoint inhibitor therapy
7 Feb, 2021 | 20:55h | UTCManagement of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy – JAMA (free for a limited period)
Audio Clinical Review: Management of Immunotherapy-Related Toxicities
Original guideline and other resources: NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities
Prospective validation of Canadian TIA Score for subsequent stroke risk after transient ischemic attack
7 Feb, 2021 | 20:54h | UTCSee calculator: Canadian TIA Score
Commentary on Twitter
Jeff Perry is at it again! The ABCD2 score lacks the ability to discriminate low and high risk patients following TIA, so Perry et al. have validated the Canadian TIA Score.
Infographic and bedside calculator: https://t.co/OcbaK1aG3t
Full publication: https://t.co/wt87PKzNkO pic.twitter.com/q3QdgVxp6x
— EM Ottawa (@emergmedottawa) February 4, 2021
Case report: SARS-CoV-2 evolution in immunocompromised patient treated with convalescent plasma
7 Feb, 2021 | 21:32h | UTCSARS-CoV-2 evolution during treatment of chronic infection – Nature
Commentary on Twitter
Just published @nature: The evolution of #SARSCoV2 in an immunocompromised patient, over > 100 days, that markedly accelerated once treated w/ convalescent plasma, with mutations that altered the response to neutralizing antibodies, by @GuptaR_lab https://t.co/SI4QL6BRXe pic.twitter.com/wqI1C2EYjQ
— Eric Topol (@EricTopol) February 5, 2021
[Press release – not published yet] Covid-19: Oxford vaccine offers less protection against South Africa variant
7 Feb, 2021 | 21:25h | UTCOxford Covid-19 vaccine trial results – University of the Witwatersrand
Commentaries: Covid: Oxford jab offers less S Africa variant protection – BBC AND Expert reaction to news reports that the Oxford/AZ vaccine gives limited protection against mild disease caused by the South African variant of SARS-CoV-2 – Science Media Centre AND Oxford/AstraZeneca COVID shot less effective against South African variant: study – Reuters
Commentary on Twitter (thread – click for more)
[Thread] 1. NEW Early data (not yet peer reviewed) shows the #AstraZeneca #CovidVaccine, that SA will start to administer this month, doesn't appear to offer protection against mild/moderate disease caused by the #501YV2 variant identified in the country. https://t.co/UWD0Xilner
— Mia Malan (@miamalan) February 7, 2021
The good and the (potentially) bad: What scientists know about variants and Covid-19 vaccines
7 Feb, 2021 | 21:23h | UTCThe good and the (potentially) bad: What scientists know about variants and Covid-19 vaccines – STAT
See also: What Will it Take to Make Covid-19 Vaccines Variant-Proof? – Wired AND What’s Going On With All These Coronavirus Variants? An Illustrated Guide – NPR AND Video: Coronavirus Variants – What They Mean – JAMA
What’s the risk of dying from a fast-spreading COVID-19 variant?
7 Feb, 2021 | 21:21h | UTCWhat’s the risk of dying from a fast-spreading COVID-19 variant? – Nature
Original study: Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01 – medRxiv
Review: “Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19
7 Feb, 2021 | 21:13h | UTC“Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19 – Anesthesia
Cohort study: Increased consumption of refined grains linked to higher risk of mortality and major cardiovascular disease events
5 Feb, 2021 | 01:30h | UTCCommentaries: Refined carbs like white bread, pasta, and pastries could increase risk of early death, a study found – Insider AND High intake of refined grains linked to higher risk of heart disease and death – The BMJ
Review: Dysphagia in older adults
5 Feb, 2021 | 01:22h | UTCDysphagia in Older Adults – Mayo Clinic Proceedings
SR/MA: Colistin nephrotoxicity
5 Feb, 2021 | 01:21h | UTC
NIH Treatment Guideline Update: “there are insufficient data to recommend either for or against the use of tocilizumab or sarilumab for the treatment of COVID-19”
5 Feb, 2021 | 01:44h | UTC
Dialysis patients have 4-fold greater risk of dying from COVID-19
5 Feb, 2021 | 01:39h | UTCNews Release: Dialysis patients have 4-fold greater risk of dying from COVID-19 – Canadian Medical Association Journal
Original Study: COVID-19 in patients undergoing long-term dialysis in Ontario – Canadian Medical Association Journal
COVID’s mental-health toll: how scientists are tracking a surge in depression
5 Feb, 2021 | 01:36h | UTCCOVID’s mental-health toll: how scientists are tracking a surge in depression – Nature
Related: Trends in US Emergency Department Visits for Mental Health, Overdose, and Violence Outcomes Before and During the COVID-19 Pandemic – JAMA Psychiatry AND Mental Health, COVID-19, and the Invisible Pandemic on the Horizon – Mayo Clinic Proceedings
State of the Art Review: Uveitis for the non-ophthalmologist
4 Feb, 2021 | 01:22h | UTCUveitis for the non-ophthalmologist – The BMJ (free for a limited period)
German 2021 guideline update on acute therapy and management of anaphylaxis
4 Feb, 2021 | 01:17h | UTC
Observational study suggests a conservative approach to inpatient hypertension may be safer
4 Feb, 2021 | 01:14h | UTCTreatment and Outcomes of Inpatient Hypertension Among Adults With Noncardiac Admissions – JAMA Internal Medicine (link to abstract – $ for full-text)
Commentary on Twitter
#Hypertension is common in the inpatient setting, but antihypertensive intensification is not. Intensification of therapy without signs of end-organ damage is associated with worse outcomes https://t.co/y1MdZNfi9P
— JAMA Internal Medicine (@JAMAInternalMed) December 29, 2020
UK Biobank study shows that COVID-19 antibodies remain for at least 6 months post-infection for the vast majority of people who have had the virus
4 Feb, 2021 | 01:32h | UTCCommentary: Covid: Antibodies last at least six months in most – BBC
RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19
4 Feb, 2021 | 01:39h | UTCInvited Commentary: Azithromycin, RECOVERY, and the power of large, simple trials – The Lancet
Study shows the viral load of index cases is a leading driver of SARS-CoV-2 transmission
4 Feb, 2021 | 01:35h | UTCCommentary: Understanding the drivers of transmission of SARS-CoV-2 – The Lancet Infectious Diseases
[Preprint] Meta-analysis: More than 50 Long-term effects of COVID-19
4 Feb, 2021 | 01:26h | UTCMore than 50 Long-term effects of COVID-19: a systematic review and meta-analysis – medRxiv
Commentary: 80% of COVID-19 Patients May Have Lingering Symptoms, Signs — More than 50 effects persisted after acute infection, meta-analysis shows – MedPage Today (free registration required)
Systematic review: No evidence that patients with asthma are at increased risk of COVID-19 diagnosis, hospitalization or death
4 Feb, 2021 | 01:24h | UTC
USPSTF recommends against screening for asymptomatic carotid artery stenosis in the general adult population
3 Feb, 2021 | 01:29h | UTCEditorials: Screening for Asymptomatic Carotid Artery Stenosis: Lack of Clinical Benefit, Potential for Harm – JAMA AND Screening for Asymptomatic Carotid Artery Stenosis in Adult Patients: Unclear Benefit but Downstream Risks – JAMA Internal Medicine AND USPSTF Recommendations for Screening for Carotid Stenosis to Prevent Stroke—The Need for More Data – JAMA Network Open
Author interview: USPSTF Recommendation: Carotid Artery Stenosis
JAMA Patient Page: Screening for Carotid Artery Stenosis